JP2013507926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507926A5 JP2013507926A5 JP2012534364A JP2012534364A JP2013507926A5 JP 2013507926 A5 JP2013507926 A5 JP 2013507926A5 JP 2012534364 A JP2012534364 A JP 2012534364A JP 2012534364 A JP2012534364 A JP 2012534364A JP 2013507926 A5 JP2013507926 A5 JP 2013507926A5
- Authority
- JP
- Japan
- Prior art keywords
- binding agent
- bispecific binding
- linker moiety
- igf
- erbb3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011230 binding agent Substances 0.000 claims description 76
- 125000005647 linker group Chemical group 0.000 claims description 49
- 230000008685 targeting Effects 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 238000000554 physical therapy Methods 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 239000013638 trimer Substances 0.000 claims description 4
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 101100059511 Homo sapiens CD40LG gene Proteins 0.000 claims description 2
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 claims description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 2
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 claims description 2
- 101000830598 Homo sapiens Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 claims description 2
- 101000851434 Homo sapiens Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims description 2
- 101000830594 Homo sapiens Tumor necrosis factor ligand superfamily member 14 Proteins 0.000 claims description 2
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 2
- 108010073807 IgG Receptors Proteins 0.000 claims description 2
- 102000009490 IgG Receptors Human genes 0.000 claims description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 239000000833 heterodimer Substances 0.000 claims description 2
- 239000000710 homodimer Substances 0.000 claims description 2
- 102000057041 human TNF Human genes 0.000 claims description 2
- 102000050320 human TNFRSF4 Human genes 0.000 claims description 2
- 102000044949 human TNFSF10 Human genes 0.000 claims description 2
- 102000058177 human TNFSF12 Human genes 0.000 claims description 2
- 102000050326 human TNFSF13B Human genes 0.000 claims description 2
- 102000051198 human TNFSF14 Human genes 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000005865 ionizing radiation Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108020001580 protein domains Proteins 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 230000009870 specific binding Effects 0.000 claims 3
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 230000012010 growth Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25142609P | 2009-10-14 | 2009-10-14 | |
| US61/251,426 | 2009-10-14 | ||
| PCT/US2010/052712 WO2011047180A1 (en) | 2009-10-14 | 2010-10-14 | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013507926A JP2013507926A (ja) | 2013-03-07 |
| JP2013507926A5 true JP2013507926A5 (cg-RX-API-DMAC10.html) | 2013-11-21 |
Family
ID=43511327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534364A Pending JP2013507926A (ja) | 2009-10-14 | 2010-10-14 | IGF−1R及びErbB3シグナル伝達を標的とする二重特異的結合剤及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20120244163A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2488199A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2013507926A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2010306774A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2777242A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2011047180A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895001B2 (en) | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| MX2012012927A (es) | 2010-05-06 | 2013-05-01 | Novartis Ag | Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6). |
| SG185416A1 (en) | 2010-05-06 | 2012-12-28 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies |
| US8691771B2 (en) | 2010-05-21 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins for tissue repair |
| ME02637B (me) | 2010-08-20 | 2017-06-20 | Novartis Ag | Antitela za receptor 3 faktora rasta epiderma (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| AU2012222833B2 (en) | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
| US20140134170A1 (en) * | 2011-03-11 | 2014-05-15 | Merrimack Pharmaceuticals, Inc. | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
| MX336197B (es) * | 2011-04-19 | 2016-01-11 | Merrimack Pharmaceuticals Inc | Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos. |
| IN2014CN03887A (cg-RX-API-DMAC10.html) * | 2011-10-27 | 2015-10-16 | Genmab As | |
| US8883735B2 (en) | 2011-11-04 | 2014-11-11 | Novartis Ag | Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs |
| CA2855864A1 (en) | 2011-11-17 | 2013-05-23 | Gundram Jung | Bi-specific antibodies for treating b-cell mediated autoimmune diseases or auto-reactive b-cells |
| CN108424456B (zh) | 2011-11-23 | 2022-04-26 | 医学免疫有限责任公司 | 特异于her3的结合分子及其用途 |
| CN104203981A (zh) * | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| KR101814370B1 (ko) * | 2011-12-27 | 2018-01-12 | 재단법인 생물기술개발중심 | 경쇄-가교된 이중특이성 항체 |
| CN104684579A (zh) * | 2012-04-02 | 2015-06-03 | 梅里麦克制药股份有限公司 | 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用 |
| IN2015DN01115A (cg-RX-API-DMAC10.html) | 2012-07-13 | 2015-06-26 | Zymeworks Inc | |
| MX2015002985A (es) * | 2012-09-07 | 2015-06-22 | Sanofi Sa | Proteinas de fusion para el tratamiento de un sindrome metabolico. |
| EP2920210B1 (en) * | 2012-11-19 | 2017-08-30 | Baliopharm AG | Recombinant bispecific antibody binding to cd20 and cd95 |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| WO2015130554A2 (en) * | 2014-02-20 | 2015-09-03 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| US20180169230A1 (en) | 2015-05-29 | 2018-06-21 | Merrimack Pharmaceuticals, Inc. | Combination cancer therapies |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| CA3000742A1 (en) | 2015-10-02 | 2017-04-06 | Silver Creek Pharmaceuticals, Inc. | Bi-specific therapeutic proteins for tissue repair |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| EP3432936A1 (en) * | 2016-03-24 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | Radio-pharmaceutical complexes |
| US10723857B1 (en) * | 2016-04-15 | 2020-07-28 | United States Of America As Represented By The Administrator Of National Aeronautics And Space Administration | Polyimide aerogels with reduced shrinkage from isothermal aging |
| US12667557B2 (en) | 2017-02-28 | 2026-06-30 | Daiichi Sankyo Company, Limited | Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate |
| CN109400711B (zh) * | 2017-05-31 | 2022-02-08 | 四川大学华西医院 | 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 |
| CA3095582A1 (en) * | 2018-04-04 | 2019-10-10 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| WO2020059772A1 (ja) | 2018-09-20 | 2020-03-26 | 第一三共株式会社 | 抗her3抗体-薬物コンジュゲート投与によるher3変異がんの治療 |
| EP3897849A1 (en) * | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| EP3999544A4 (en) * | 2019-07-19 | 2023-08-09 | Wuxi Xdc Singapore Private Limited | POLYPEPTIDE COMPLEX FOR CONJUGATION AND ITS USE |
| KR20230156921A (ko) * | 2021-03-12 | 2023-11-15 | 젠맵 에이/에스 | 비-활성화 항체 변이체 |
| JPWO2024248123A1 (cg-RX-API-DMAC10.html) | 2023-06-02 | 2024-12-05 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JP4355571B2 (ja) | 2001-07-19 | 2009-11-04 | ウニベルジテート チューリッヒ | ヒト可変ドメインの改変 |
| AU2006247039B2 (en) | 2005-05-19 | 2011-03-03 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| NZ579644A (en) * | 2007-02-16 | 2012-05-25 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| MX2009012343A (es) * | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| CN101952312A (zh) * | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| KR20090014471A (ko) | 2007-08-06 | 2009-02-11 | 삼성전자주식회사 | 잉크젯 화상형성장치 |
| JP5639039B2 (ja) * | 2008-04-11 | 2014-12-10 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| MX336197B (es) * | 2011-04-19 | 2016-01-11 | Merrimack Pharmaceuticals Inc | Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos. |
-
2010
- 2010-10-14 JP JP2012534364A patent/JP2013507926A/ja active Pending
- 2010-10-14 AU AU2010306774A patent/AU2010306774A1/en not_active Abandoned
- 2010-10-14 EP EP10775965A patent/EP2488199A1/en not_active Ceased
- 2010-10-14 CA CA2777242A patent/CA2777242A1/en not_active Abandoned
- 2010-10-14 WO PCT/US2010/052712 patent/WO2011047180A1/en not_active Ceased
-
2012
- 2012-04-10 US US13/443,660 patent/US20120244163A1/en not_active Abandoned
-
2016
- 2016-12-07 US US15/371,536 patent/US20170210809A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gandullo-Sánchez et al. | HER3 in cancer: from the bench to the bedside | |
| US20250127858A1 (en) | Novel cytokine prodrugs | |
| US10428149B2 (en) | Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof | |
| BR112021005907A2 (pt) | citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit | |
| WO2021062406A1 (en) | Cytokine prodrugs and dual-prodrugs | |
| JP2020501531A5 (cg-RX-API-DMAC10.html) | ||
| JP2016520586A5 (cg-RX-API-DMAC10.html) | ||
| CN108463245A (zh) | 具有修饰的j链的结合分子 | |
| RS62151B1 (sr) | Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu | |
| JP7097293B2 (ja) | ヒトFc受容体に結合する融合タンパク質 | |
| JP7752132B2 (ja) | Her2を標的とする抗原結合構築物及び用途 | |
| JP2020503860A (ja) | 免疫応答のコンディショナルアゴニスト | |
| JP2018501211A5 (cg-RX-API-DMAC10.html) | ||
| WO2020068774A1 (en) | System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies | |
| WO2023049909A1 (en) | Composition of recombinant antigen binding molecules and method of making and using thereof | |
| WO2021110990A1 (en) | Anti-clec-1a antibodies and antigen-binding fragment thereof | |
| WO2024193705A1 (en) | Tnf superfamily member immunocytokine and uses thereof | |
| WO2024078479A1 (zh) | 一种异源二聚体融合蛋白及其应用 | |
| CN103172741B (zh) | 全人源抗egfr抗体 | |
| Bakherad et al. | Engineering an anti-granulocyte colony stimulating factor receptor nanobody for improved affinity | |
| WO2022214664A1 (en) | Improved interferon-gamma mutant | |
| CN118139884A (zh) | 人源化抗clec-1a抗体和其抗原结合片段及其模拟物 | |
| WO2021244553A1 (zh) | 一种抗pd-l1和egfr的四价双特异性抗体 | |
| RU2844389C2 (ru) | Her2-нацеленные антигенсвязывающие конструкции и их использование | |
| WO2012024659A2 (en) | Antibody-based constructs directed against tyrosine kinase receptors |